Cara Therapeutics
Oct 31, 2017

Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting

STAMFORD, Conn., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the presentation of a late-breaking CR845 poster at the American College of Rheumatology ACR/ARHP Annual Meeting, to be held November 3-8, 2017 in San Diego.

The poster presentation will include clinical trial data from the Company's completed Phase 2b study of Oral CR845 in patients with osteoarthritis of the hip or knee. CR845 is Cara's first-in-class, peripherally selective kappa opioid receptor agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.

Details for the presentation are as follows:

CR845 Poster Presentation:

Title: "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee"
Presentation Number:
15L
Date / Time:Tuesday, November 7, 2017; 9:00 - 11:00 a.m. PT
Presenter:Sukirti Bagal, M.D., M.P.H., Senior Medical Director, Cara Therapeutics

For information about the ACR/ARHP Annual Meeting, visit https://www.rheumatology.org/Annual-Meeting.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.


INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

Source: Cara Therapeutics, Inc.

News Provided by Acquire Media